

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

62483

DRAFT FINAL PRINTED LABELING

Grifulvin V

TRADEMARK
(griseofulvin microsize)

Tablets / Suspension

Description

Griseofulvin microsize is an antibiotic derived from a species of *Penicillium*.

Actions

GRIFULVIN V (griseofulvin microsize) acts systemically to inhibit the growth of Trichophyton, Microsporum, and Epidermophyton genera of fungi. Fungistatic amounts are deposited in the keratin, which is gradually exfoliated and replaced by noninfected tissue.

Griseofulvin absorption from the gastrointestinal tract varies considerably among individuals, mainly because of insolubility of the drug in aqueous media of the upper G.I. tract. The peak serum level found in fasting adults given 0.5 gm. occurs at about four hours and ranges between 0.5 and 2.0 mcg./ml.

It should be noted that some individuals are consistently "poor absorbers" and tend to attain lower blood levels at all times. This may explain unsatisfactory therapeutic results in some patients. Better blood levels can probably be attained in most patients if the tablets are administered after a meal with a high fat content.

Indications

Major indications for GRIFULVIN V griseofulvin microsize are:

- Tinea capitis (ringworm of the scalp)
- Tinea corporis (ringworm of the body)

- Tinea pedis (athlete's foot)
- Tinea unguium (onychomycosis; ringworm of the nails)
- Tinea cruris (ringworm of the thigh)
- Tinea barbae (barber's itch)

GRIFULVIN V (griseofulvin microsize) inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as:

- Trichophyton rubrum
- Trichophyton tonsurans
- Trichophyton mentagrophytes
- Trichophyton interdigitalis
- Trichophyton verrucosum
- Trichophyton sulphureum
- Trichophyton schoenleinii
- Microsporum audouinii
- Microsporum canis
- Microsporum gypsum
- Epidermophyton floccosum
- Trichophyton megnini
- Trichophyton gallinae
- Trichophyton crateriform

Note: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone.

It is *not* effective in:

- Bacterial infections
- Candidiasis (Moniliasis)
- Histoplasmosis
- Actinomycosis
- Sporotrichosis
- Chromoblastomycosis
- Coccidioidomycosis
- North American Blastomycosis
- Cryptococcosis (Torulosis)
- Tinea versicolor
- Nocardiosis

Contraindications

This drug is contraindicated in patients with porphyria, hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin.

Warnings

Usage in Pregnancy: Safe use of GRIFULVIN V (griseofulvin microsize) in pregnancy has not been established.

Prophylactic Usage: Safety and efficacy of prophylactic use of this drug has not been established.

Chronic feeding of griseofulvin, at levels ranging from 0.5-2.5% of the diet, resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous administration of relatively small doses of griseofulvin once a week during the first three weeks of life has also been reported to induce hepatomata in mice. Although studies in other animal species have not yielded evidence of tumorigenicity, these studies were not of adequate design to form a basis for conclusions in this regard.

In subacute toxicity studies, orally administered griseofulvin produced hepatocellular necrosis in mice, but this has not been seen in other species. Disturbances in porphyrin metabolism have been reported in griseofulvin-treated laboratory animals. Griseofulvin has been reported to have a colchicine-like effect on mitosis and cocarcinogenicity with methylcholanthrene in cutaneous tumor induction in laboratory animals.

Reports of animal studies in the Soviet literature state that a griseofulvin preparation was found to be embryotoxic and teratogenic on oral administration to pregnant Wistar rats. Rat reproduction studies done thus far in the United States and Great Britain have been inconclusive

in this regard, and additional animal reproduction studies are underway. Pups with abnormalities have been reported in the litters of a few bitches treated with griseofulvin.

Suppression of spermatogenesis has been reported to occur in rats but investigation in man failed to confirm this.

Precautions

Patients on prolonged therapy with any potent medication should be under close observation. Periodic monitoring of organ system function, including renal, hepatic and hemopoietic, should be done.

Since griseofulvin is derived from species of penicillin, the possibility of cross sensitivity with penicillin exists; however, known penicillin-sensitive patients have been treated without difficulty.

Since a photosensitivity reaction is occasionally associated with griseofulvin therapy, patients should be warned to avoid exposure to intense natural or artificial sunlight. Should a photosensitivity reaction occur, lupus erythematosus may be aggravated.

Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.

Adverse Reactions

When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria and rarely, angioneurotic edema, and may necessitate withdrawal of therapy and appropriate countermeasures. Paresthesias of the hands and feet have been reported rarely after extended therapy. Other side effects reported occasionally are oral thrush, nausea,

Grifulvin V

(griseofulvin microsize)

Tablets / Suspension

Orally effective
antifungal agent for
ringworm infections
of the hair, skin,
and nails

Improved absorption -
Higher blood levels

DERMATOLOGICAL DIVISION
ORTHO PHARMACEUTICAL
CORPORATION
Raritan, New Jersey 08869
a Johnson & Johnson Company

Issued November 1982

631-10-560-1

vomiting, epigastric distress, diarrhea; headache, fatigue, dizziness, insomnia, mental confusion and impairment of performance of routine activities.

Proteinuria and leukopenia have been reported rarely. Administration of the drug should be discontinued if granulocytopenia occurs.

When rare, serious reactions occur with griseofulvin, they are usually associated with high dosages, long periods of therapy, or both.

Dosage and Administration

Accurate diagnosis of the infecting organism is essential. Identification should be made either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.

Medication must be continued until the infecting organism is completely eradicated as indicated by appropriate clinical or laboratory examination. Representative treatment periods are tinea capitis, 4 to 6 weeks; tinea corporis, 2 to 4 weeks; tinea pedis, 4 to 8 weeks; tinea unguium - depending on rate of growth - fingernails, at least 4 months; toenails, at least 6 months.

General measures in regard to hygiene should be observed to control sources of infection or reinfection. Concomitant use of appropriate topical agents is usually required, particularly in treatment of tinea pedis since in some forms of athlete's foot, yeasts and bacteria may be involved. Griseofulvin will not eradicate the bacterial or monilial infection.

Adults

A daily dose of 500 mg. will give a satisfactory response in most patients with tinea corporis, tinea cruris, and tinea capitis.

For those fungus infections more difficult to eradicate such as tinea pedis and tinea unguium, a daily dose of 1.0 gram is recommended.

Children

Approximately 5 mg. per pound of body weight per day is an effective dose for most children. On this basis the following dosage schedule for children is suggested:

Children weighing 30 to 50 pounds - 125 mg. to 250 mg. daily.

Children weighing over 50 pounds - 250 mg. to 500 mg. daily.

How Supplied

GRIFULVIN V (griseofulvin microsize) 250 mg. Tablets in bottles of 100 (white, scored, imprinted "ORTHO 211").

GRIFULVIN V (griseofulvin microsize) 500 mg. Tablets in bottles of 100 and 500 (white, scored, imprinted "ORTHO 214").

Dispense GRIFULVIN V tablets in well-closed container as defined in the official compendia.

GRIFULVIN V (griseofulvin microsize) Suspension 125 mg. per 5 cc. in bottles of 4 fl. oz.

Dispense GRIFULVIN V suspension in tight, light-resistant container as defined in the official compendia.

©OPC 1982


Printed in U.S.A.

U.S. Patent Nos. 2,900,304; 3,330,727 631-10-560-1

BOTTLE LABEL

NDC 0062-0206-04

Grifulvin V
TRADEMARK
(griseofulvin microsize)
Suspension



Usual Dosage

Adults: Four teaspoonfuls daily.
Children: One to four teaspoonfuls daily depending on age and weight.
For information for use, see accompanying product literature.
This is a bulk container. Not intended for household use.
Dispense in light, light-resistant container, as defined in the official Compendia.

© OPC 1982 U.S. Patents 2,900,304 3,330,727 Made in U.S.A. 602-10-569-1

00-00040